From the Journals

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

Share

  • 1

    Higher-dose semaglutide (Wegovy) shows increased ION risk.

  • 2

    Risk is 4.7 times higher compared to lower-dose (Ozempic).

  • 3

    31,774 reports of semaglutide associated with ION identified.

  • 4

    Strongest risk signal found in men taking Wegovy.

  • 5

    No ION reports with Rybelsus.

  • 6

    Analysis cannot establish causality.

  • 7

    Recommendations for longitudinal studies to assess risk.

  • 8

    Emphasis on personalized therapy for GLP-1 administration.

Original Source(s)

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

  • by Kerri Miller

  • March 11, 2026

  • 5 min

Related Content

Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.

Beyond IOP: The Mood Effects of CAIs

Evidence from large US dataset suggests topical carbonic Anhydrase Inhibitors may increase depression risk in glaucoma patients

  • March 12, 2026

  • 5 min
The Most Influential Conversations in Ophthalmology Aren’t on the Podium

How WhatsApp is quietly shaping clinical practice